To IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 1999; 163: 6606613. 64 Ray M, Yu S, Sharda DR, Wilson CB, Liu Q, Kaushal N et al. Inhibition of TLR4induced IkappaB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein. J Immunol 2010; 185: 7309316. 65 Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA, Waltz SE. Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology 2011; 53: 1618628. 66 Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, Huber N et al. Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock 2010; 33: 19704. 67 Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC et al. Signaling by toll-like receptor 2 and four agonists results in differential gene expression in murine macrophages. Infect Immun 2001; 69: 1477482.Trifloxystrobin Data Sheet 68 Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; six: 83648. 69 Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgamma and lymphocytes avert major tumour improvement and shape tumour immunogenicity. Nature 2001; 410: 1107111. 70 Trinchieri G. Form I interferon: pal or foe J Exp Med 2010; 207: 2053063. 71 O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM et al. Cancer immunoediting by the innate immune program within the absence of adaptive immunity. J Exp Med 2012; 209: 1869882. 72 Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80: 1298307. 73 Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 95364. 74 Nathan C. Metchnikoff’s Legacy in 2008. Nat Immunol 2008; 9: 69598. 75 Mosser DM, Edwards JP. Exploring the complete spectrum of macrophage activation. Nat Rev Immunol 2008; eight: 95869. 76 Mosser DM, Zhang X. Activation of murine macrophages. Curr Protoc Immunol 2008; Chapter 14: Unit 14.2. 77 Martinez FO, Helming L, Gordon S. Option activation of macrophages: an immunologic functional viewpoint.Laccase, Microorganisms Purity Annu Rev Immunol 2009; 27: 45183.PMID:24238102 78 Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse types of macrophage activation and polarization. Trends Immunol 2004; 25: 67786. 79 Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008; Chapter 14: Unit 14.1. 80 Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 90307.35 36384144 4547495157This work is licensed below the Inventive Commons Attribution-NonCommercial-No Derivative Operates 3.0 Unported License. To view a copy of this license, take a look at http://creative commons.org/licenses/by-nc-nd/3.0/The Supplementary Details that accompanies this paper is available around the Immunology and Cell Biology web site (http://www.nature/icb)Immunology and Cell Biology
Dendritic cells (DC) are the principal immune regulators placed in the interface of innate and adaptive immunity. They function as antigen-presenting cells and will be the only cells using the capability to induce a principal immune response in naive T lymphocytes.1 In vitro DC systems might be utilized as models to greater unde.